- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Analysts demand news on next Lilly blockbuster
April 18, 2011
J.K. WallEli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not
connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just
want to know when the next blockbuster will be coming.
MoreLilly shares falter after quarterly earnings report
April 18, 2011
J.K. WallEli Lilly and Co.’s first-quarter profit beat the expectations of Wall Street analysts, but its stock price slipped
anyway Monday morning, along with the broader market.
MoreCharges drive down first-quarter profit at Lilly
April 18, 2011
J.K. WallFirst-quarter profit fell at Eli Lilly and Co. as the company recorded restructuring charges due to its downsizing and higher
research costs as it tries to develop new drugs to help it shrug off its looming patent expirations.
MoreFDA wants further testing of Lilly pancreas drug
April 16, 2011
Associated PressEli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed
pancreas drug before it resubmits an application to have the drug approved for sale.
MoreLilly’s Bydureon wins backing of European drug panel
April 15, 2011
Bloomberg NewsThe drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union.
The Commission usually makes a decision on CHMP recommendations within two to three months.
MoreSix faces behind Indianapolis business Twitter handles
April 9, 2011
Gabrielle PoshadloMeet the people who tweet for Indianapolis Symphony Orchestra, AAA, Butler University and other local businesses.
MoreChina making big gains in drug R&D jobs state covets
April 9, 2011
Greg AndrewsThe total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is
one-third of that, said a company executive.
MoreAntidepressants linked to narrowed arteries
April 4, 2011
The study included Eli Lilly and Co. drug Cymbalta, which racked up sales of $3.5 billion last year for the Indianapolis-based
drugmaker.
MoreDrugmaker Lilly launches global service program
March 31, 2011
Associated PressEli Lilly and Co. is starting a service program that sends employees around the world to help developing communities and learn
about other cultures, as the drugmaker looks to international markets.
MoreDemographic shift steers Lilly's Asian operations
March 26, 2011
Greg AndrewsChina remains a small market for Eli Lilly and Co. It generated $320 million in sales for the company in 2010, just 1.3 percent
of its $23 billion in sales worldwide. But Lilly has big ambitions in China and is racing to capitalize on its rapid economic
growth.
MoreDrugmakers call off animal-health deal, possible asset sale
March 22, 2011
IBJ Staff and Bloomberg NewsDrugmakers Merck & Co. and Sanofi-Aventis SA have abandoned plans to combine their animal-health businesses after wrestling
with regulators for a year over potential divestitures.
Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies
considered selling.
MorePROXY CORNER: Eli Lilly and Co.
March 19, 2011
IBJ StaffEli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells
pharmaceutical products for humans and animals.
MoreRegulators delay approval of Lilly's Alzheimer’s screen
March 18, 2011
Bloomberg NewsThe Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
MoreTrade agency to probe Lilly's infringement claim
March 17, 2011
Bloomberg NewsEli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated
by a U.S. trade agency with the power to block imports of the copycat drug.
MoreLechleiter: After the deluge, we'll be fine
March 16, 2011
J.K. WallEli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver
his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly
will be just fine after it has sustained the damage of the next three years.
MoreLilly agrees to buy European animal health company
March 14, 2011
J.K. WallElanco, the animal health division of Eli Lilly and Co., has agreed to acquire Jannsen Animal Health, a subsidiary of New
Jersey-based Johnson & Johnson, pending regulatory approval. Financial terms of the deal were not disclosed.
MoreLilly suffers another bruise from Novo
March 9, 2011
J.K. WallThe failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the
highly touted diabetes drug.
MoreLilly's Bydureon falls short of competitor in study
March 3, 2011
Bloomberg NewsBydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t
control the disease better than Novo Nordisk A/S’s Victoza in a study.
MoreUPDATE: Bioanalytical researcher opening lab in Indianapolis
March 1, 2011
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the
workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of
a partnership.
MoreNorth of South development to start this summer
March 1, 2011
Tom HartonNow that financing for Buckingham Cos.’ massive project has the city’s blessing, the local developer is turning
its full attention to construction of the 14-acre, mixed-use complex.
MoreEli Lilly neuroscience chief resigns
February 25, 2011
J.K. WallDavid Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according
to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in
late-stage human testing to treat Alzheimer’s and depression.
MoreUPDATE: Lilly settles pollution suit for $337,500
February 24, 2011
Scott OlsonA complaint filed Wednesday by the U.S. government says Lilly's plant on South Harding Street is emitting high levels of acetonitrile
and methanol, considered hazardous air pollutants by the EPA.
MoreLilly looks to double pipeline size again
February 23, 2011
J.K. WallIndianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to
60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this
alternative pipeline.
MoreEmerging markets give Lilly hope in patent crunch
February 19, 2011
J.K. WallIn a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting
the drugmaker to pour money into emerging markets in an attempt to prop up revenue.
MoreLilly takeover provision to be voted on again
February 11, 2011
Scott OlsonThe effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly's board is on the agenda
of the company's April 18 annual meeting.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
First, the Athenaeum is going to have to get past the hurdle with the Lockerbie residents and the agreement that the parcel would be residential. Second, and in my opinion, this prime piece of property should include parking, PLUS, a black box theater(s), some market rate and affordable artist housing and a plan to renovate and reconfigure the second story theater. I would negotiate to add the DeHaan property surface parking lot into the development mix, place a one story surface parking garage on the DeHaan lot on the street level (for the Dehaan tenants use during the daytime) and add a second story to the garage that would become an addition to the current second story theater and then change the direction of the theater by moving the stage across the alley and on top of the DeHaan lot parking. You can add all the stage elements that are currently missing from the Athenaeum stage to make it more attractive for use by Ballet, Opera and traveling productions. Plus, the theater changes would probably help solve some of the soundproofing issues. Alas,it does not seem to be a part of the strategic plan to conduct a study to determine best use of the property. Seems like the current plan is a quick and easy move that ignores the property best use/potential and any strategic property planning for the effect on future generations.
I recall that MSA's pilings are still in the ground and hard to remove. It’s not likely any proposal will include significant underground construction/parking because of this. Start adding 2 floors of retail, 8 floors of parking and 5-10 floors of possible hotel, and/or 10-20 floors of residential, and you are at 30 floors already with possible expansion of all the uses. But then again I could be wrong.
Accoriding to their website there is no deadline to the Do Not Call list. What is this article referring to??
On what planet are they entitled to this largesse from the stockholders? These people make multi-million dollar salaries: Pay for your own personal travel.
It matters because they're already paid enormously fat salaries: Pay for your own personal travel. Being "taxed on it" isn't a valid excuse--so what? They're still being gifted a raft of luxury perks from somebody else's money on top of an enormous, lavish salary.